Lessons Learned from Alternative Catalytic Funding Models
Malcom Riley, Innovations in Healthcare & FHI Ventures
New funding models created to address complex social problems are increasingly changing the donor landscape for SGBs. The rising prominence of “portfolio funds” makes it important to better understand their design, management, and evaluation. This session will draw on the experiences of a leading funder, supporting ecosystem intermediaries, and evaluation partners to discuss best practices and challenges in launching such initiatives. Attendees will gain insight into how FHI Ventures, The Pfizer Foundation’s Global Health Innovation Grants (GHIG) program, and Innovations in Healthcare are working together to deploy flexible funding to de-risk investments, scale promising social enterprises, and measure portfolio impact.
Flexible Funding. Catalytic Funding. Social Impact. Portfolio Funds. Impact Measurement.
Lisa Bourget, Deputy Director, Innovations in Healthcare Wellington Pak, President, FHI Ventures
Darren Back, Senior Director, Social Investments & Global Health Programs, Pfizer Inc and Pfizer Foundation Andrew Foote, CEO & Co-Founder, Sanivation Eddy Agbo, CEO & Founder, Fyodorbio Kevin Barrow, CEO, Mark Labs
1) Pfizer Foundation Partners with Innovations in Healthcare: https://www.innovationsinhealthcare.org/the-pfizer-foundation-partners-with-innovations-in-healthcare-through-grants-program/ 2) FHI Ventures launches social impact investing subsidiary: https://www.fhi360.org/news/fhi-360-launches-fhi-ventures-social-impact-investing-subsidiary 3) How Flexible Funding can drive social enterprises and improved health outcomes: https://www.innovationsinhealthcare.org/document/pfizer-foundation-global-health-innovation-grants-program-how-flexible-funding-can-drive-social-enterprise-and-improved-health-outcomes/